Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rodatristat Ethyl Food Effect and Supratherapeutic Dose Study
NCT05684640Phase 1Completed
- Sponsor
- Altavant Sciences
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rodatristat in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Altavant Sciences. Primary endpoints: Pharmacokinetics of rodatristat ethyl, rodatristat, and metabolite(s) (Food Effect) at 6 Days and Pharmacokinetics of rodatristat ethyl, rodatristat, and metabolite(s) (Supratherapeutic Dose) at 11 Days. Started Sep 2022; status: completed.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05684640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684640.